<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477033</url>
  </required_header>
  <id_info>
    <org_study_id>ML9449</org_study_id>
    <nct_id>NCT02477033</nct_id>
  </id_info>
  <brief_title>Impact of Butyricicoccus Pullicaecorum in Healthy Subjects</brief_title>
  <official_title>A Placebo-controlled Cross-over Randomized Study to Investigate the Impact of Butyricicoccus Pullicaecorum in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During this project the safety, tolerability and effect on gut microbiota of oral
      administration of Butyricicoccus pullicaecorum was investigated in healthy human volunteers
      by a placebo-controlled cross-over randomized study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention periods were 4 weeks, with daily intake of 1 capsule. Wash-out periods were 3
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of Butyricicoccus pullicaecorum intake (composite outcome measure), measured by abdominal complaints surveys, standard blood tests and fecal calprotectin measurements</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of Butyricicoccus pullicaecorum intake on gut microbiota composition, measured by 16S rDNA Illumina profiling of the bacterial communities</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of Butyricicoccus pullicaecorum intake on gut microbiota activity, measured by GC-MS analysis of the fecal volatile organic compounds</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Butyricicoccus pullicaecorum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (maltodextrin)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lyophilized maltodextrin, encapsulated with a pH-resistent coating.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Butyricicoccus pullicaecorum 25-3T</intervention_name>
    <arm_group_label>Butyricicoccus pullicaecorum</arm_group_label>
    <other_name>LMG 24109T; CCUG 55265T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <arm_group_label>Placebo (maltodextrin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18 and 28 kg/mÂ²

          -  Good general health

          -  Regular eating pattern (3 meals/day on at least 5 days/week)

        Exclusion Criteria:

          -  Chronic gastrointestinal disease (Crohn's disease, ulcerative colitis, irritable bowel
             syndrome, chronic constipation or chronic diarrhea)

          -  Surgery of the gastrointestinal tract (except for an appendectomy)

          -  Use of antibiotics during the month preceding the study

          -  Use of medication or dietary supplements influencing gut transit or intestinal
             microbiota during the month preceding the study. Examples of such medication/dietary
             supplements are antispasmodics (e.g. buscopan), antidiarrheal medication (e.g.
             imodium), probiotic medication (e.g. lacteol, enterol)

          -  Intake of pre- or probiotics during the study or during the month preceding the study

          -  Being on a weight-loss diet during the study or during the month preceding the study

          -  Extreme dietary habits (e.g. vegan, Atkins diet, Montignac diet)

          -  Females who are pregnant, lactating or planning to become pregnant during the study
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KULeuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Kristin Verbeke</investigator_full_name>
    <investigator_title>Professor Kristin Verbeke</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

